Эпигаллокатехин и рак

5.2. Induction of apoptosis and cell cycle arrest

Apoptosis induction by EGCG is more prominent in many cancer cells without affecting normal cells because NFκB is activated in the cancer cells (Table 1). Although EGCG has been shown to affect a number of factors associated with cell cycle progression, the direct inhibition of cyclin-dependent kinases is considered as the primary event [4]. EGCG-induced apoptosis in tumor cells may be mediated through NFκB inactivation [15]. In vitro and in vivo studies demonstrated that the inactivation of NFκB by EGCG was associated with enhancement of phosphorylation-dependent degradation of IkBα, subsequent increases in nuclear translocation of p65 protein and inhibition of IKK activity [50]. The induction of different negative regulators of the cell cycle may be the consequence of this inhibition. EGCG also induces the expression of p21 and p27 while decreasing the expression of cyclin D1 and the phosphorylation of retinoblastoma. However, EGCG inhibited LPs-induced phosphorylation of IKK, but failed to affect NFκB luciferase reporter gene activation in human colon cancer (HT-29) cells, suggesting that EGCG modulation of NFκB transcriptional activity is not necessarily dependent on IkBα degradation and subsequent release of NFκB proteins (Table 1;[51]).

EGCG down-regulates the NFκB inducing kinase expression in human lung cancer cell PC-9 [52]. Activation of NFκB promotes transcriptional up-regulation of Bcl-2 and Bcl-XL. Negative regulation of NFκB by EGCG decreases the expression of the proapoptotic protein Bcl-2 [52]. In human prostate carcinoma LNCaP cells, treatment with EGCG induced apoptosis and was associated with stabilization of p53 and also with a down-regulation of NFκB activity, resulting in a decreased expression of the anti-apoptotic protein Bcl-2 [53]. EGCG (70% lethal dose) at the suprapharmacological concentration of 10 μg/ml increased the proportion of HNSCC cells in the G1 phase, decreased cyclin D1 protein expression and increased the levels of p21WAF1/CIP1 and p27KIP1 proteins [54].

Many recent studies demonstrated that EGCG trigger cell growth arrest pathways at G1 stage of cell cycle through regulation of cyclin D1, cdk4, cdk6, p21/WAF1/CIP1 and p27/KIP1, and induced apoptosis through generation of ROS and caspase-3 and caspase-9 activation [23]. EGCG inhibited expressions of Bcl-2 and Bcl-XL and induced expressions of Bax, Bak, Bcl-XS and PUMA. Furthermore, ras, raf-1 activities and ERK1/2 were down regulated, whereas the activities of MEKK1, JNK1/2 and p38 MAP kinases were upregulated [23]. Inhibition of craf-1 or ERK enhanced EGCG-induced apoptosis, whereas inhibition of JNK or p38 MAP kinase inhibited EGCG-induced apoptosis. EGCG promoted the activation of p90 ribosomal protein S6 kinase, and induced the activation of c-jun. Xenograft and TRAMP models have shown that green tea or EGCG can decrease the tumorigenic potential of prostate cancer [23]. Treatment of MCF7 breast cancer cells with EGCG (30 μM) inhibited cell cycle arrest in G0/G1 phase. In prostate cancer cells, EGCG (10–80 μM) increased the expression of p16, p18, p21, p27 and p53, which are associated with negative regulation of cell cycle progression (Table 1). Overall, these findings suggest that green tea and its constituents induce growth arrest and apoptosis through multiple mechanisms and can be used for chemoprevention to target cancer cells. EGCG induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2, survivin and XIAP in prostate stem cancer cells. Furthermore, EGCG inhibits epithelial-mesenchymal transition by inhibiting the expression of vimentin, slug, snail and nuclear β-catenin, and the activity of LEF-1/TCF responsive reporter, and also retards CSC’s migration and invasion, suggesting the blockade of signaling involved in early metastasis [55]. Interestingly, quercetin synergizes with EGCG in inducing apoptosis, and blocking CSC’s migration and invasion. These data suggest that EGCG either alone or in combination with quercetin can eliminate CSC’s-characteristics.

5.3. Effect on phase I and II enzymes

One of the most important mechanisms of chemoprevention by cruciferous plants extracts appears to be induction of phase II enzymes and inhibition of phase I enzymes. Procarcinogenic metabolism can be altered by EGCG by inhibiting phase-I drug-metabolizing enzymes CYPs, increasing the activity or modulating the gene expression of phase II conjugating-enzymes which can regulate several biological events such as acetylation, methylation, glucuronidation, sulphation and conjugation (Table 1). In vitro studies have demonstrated that EGCG possesses a strong inhibitory effect on CYP1A1 at the transcriptional level [60]. Phenolic compounds can induce phase II conjugating enzymes, they can be considered as potential candidates for preventing tumor development [60]. EGCG increased the activity of the phase II detoxifying enzymes GST and NQO in mouse liver, breast and prostate cancer cells. Similarly, drinks rich in tea phenols increased QR activity in the Hepa1c1c7 cells and in general, EGCG prevented glutathione depletion and ROS formation after an oxidative injury caused by different carcinogens which are formed reactive metabolites such as prooxidants [61]. Consequently, tea also showed in vitro a protective effect on rat hepatic extracts, which was associated with a reduced level of CYP2E and an enhanced activity of phase II detoxifying enzyme UDPGT, suggesting that EGCG can regulate phase I and phase II drug metabolizing enzymes, although GST activity was unaffected [60]. An ARE has been found in the promoters of antioxidant proteins (SOD, Gpx, and CAT) and several drug-metabolizing enzymes (GST, and GR). Several signaling pathways have been involved in the activation of the ARE that binds transcription factor Nrf-2. In a study, it has been observed that in human hepatoma HepG2 cells, an EGCG rich green tea polyphenol extract induced the transcriptional potency of phase II detoxifying enzymes through ARE and decreased in Nrf-2-ARE binding in lung adenocarcinoma A549 cells [62].

5.4. Modulation of intracellular signaling cascades

5.4.1. Inhibition of NFκB

NFκB is a family of closely related protein dimers or oxidative stress–sensitive transcription factor that bind to a common sequence motif in DNA called the kB site [15]. The identification of the p50 subunit of NFκB as a member of the REL family of viruses provided the first evidence that NFκB is linked to cancer. NFκB is sequestered in the cytoplasm in an inactive form through interaction with IkB. NFκB is activated by free radicals, inflammatory stimuli, cytokines, carcinogens, tumor promoters, endotoxins, γ-radiation, UV light, and X-rays. Upon activation, it is translocated to the nucleus, where it induces the expression of more than 200 genes that have been shown to suppress apoptosis and induce cellular transformation, proliferation, invasion, metastasis, chemo-resistance, radio-resistance, innate immunity and inflammation.

Recent results also totally confirmed its pivotal roles in suppressing apoptosis in cancer cells [15]. Phosphorylation and activation of IkB kinase is controlled by an NFκB-inducing kinase and there is crosstalk between activation of the MAP kinase/ERK pathway, and the NFκB - inducing kinase/InB kinase/ NFκB pathway. In the cytosol, NFκB is inactive when bound to I-kB (Fig. 2). The phosphorylation of I-kB by IKKs leads to proteasome dependent degradation of I-kB, resulting NFκB free. NFκB can activate the expression of a set of NFκB responsive genes when translocate into the nucleus. EGCG has been shown to inhibit the activation of NFκB in H891 head and neck cancer cells and MDA-MB-231 breast cancer cells [63]. Treatment of EGCG dose- and time-dependently increased I-kB level, and inhibited NFκB nuclear translocation in A431 epidermoid carcinoma cells [64]. In normal human epidermal keratinocytes, UVB irradiation-induced NFκB activation was associated with increased I-kB phosphorylation and degradation and EGCG was shown to inhibit NFκB activation and nuclear translocation [15]. Although, ROS have been suggested to be involved in the activation of the NFκB signaling system, and that its suppression by EGCG is due to its strong antioxidant and free radical quenching activities [65]. It has been shown that the galloyl and phenolic groups at the 3’ position on EGCG are responsible for its strong anti-inflammatory properties [27]. EGCG has been shown to inhibit NFκB activity in human colon cancer cells [15]. EGCG suppresses the TNF-induced activation of IKK that leads to the inhibition of TNF-dependent phosphorylation and degradation of Ik-Ba and translocation of the p65 subunit. Based on its ability to inhibit other kinases, emodin may act directly on the IKK complex to block phosphorylation of IkBα. Yang et al. [13] found that EGCG suppresses NFκB activation by inhibiting IKK activity. Some act by suppressing Ik-Bα degradation and p65 translocation or NFκB –DNA binding activity. Treatment with EGCG in a dose- and time-dependent manner was found to inhibit UVB-mediated activation of NFκB in normal human epidermal keratinocytes [66]. Gupta et al. [10] identified NFκB/p65 component of the NFκB complex as a target for specific cleavage by caspases during EGCG-mediated apoptosis. Thus, one of the probable mechanisms by EGCG exercise their anti-tumor property is through the suppression of the NFκB signaling pathway.

5.4.2. Activation of FOXO transcription factors

FOXO transcription factors including FOXO1, FOXO3a, and FOXO4, exert critical biological functions in response to genotoxic stress. In mammals four FOXOs proteins are known [67]. FOXOs induce cell cycle arrest, repair damaged DNA, or initiate apoptosis by modulating genes that control these processes. The importance of FOXO factors ascribes them under multiple levels of regulation including phosphorylation, acetylation/deacetylation, ubiquitination and protein-protein interactions [67]. This function of FOXO is essential for the regulation of cancer cells and CSCs and progenitor cell pool in the hematopoietic system [67]. Recently, we have demonstrated that EGCG, resveratrol, sulforaphane inhibited cell proliferation and colony formation, and induced apoptosis through caspase-3 activation in pancreatic cancer cells [58, 68]. The inhibition of PI3K/AKT and MEK/ERK pathways activated FOXO transcription factors. EGCG inhibited phosphorylation of AKT and ERK, and activated FOXO transcription factors, leading to cell cycle arrest and apoptosis and further enhanced FOXO activity and apoptosis [21].

5.4.3. Inhibition of AP-1 and MAP kinases

AP-1 was originally identified by its binding to a DNA sequence in the SV40 enhancer. AP-1 transcription factor is a protein dimer composed of homo- or heterodimers members of the basic region leucine zipper protein superfamily, specifically, the Jun, Fos, and activating transcription factor proteins. Many stimuli, most notably serum, growth factors, and oncoproteins, are potent inducers of AP-1 activity; it is also induced by TNF and IL-1, as well as by a variety of environmental stresses, such as UV radiation. High AP-1 activity or activation of AP-1 has also been shown to be involved in the tumor promotion and progression of various types of cancers, such as lung, breast, and skin cancer. AP-1 has been implicated in regulation of genes involved in apoptosis and proliferation and may promote cell proliferation by activating the cyclin D1 gene, and repressing TSGs, such as p53, p21cip1/waf1 and p16 [15]. Green tea polyphenol EGCG was shown to inhibit 12-O-tetradecanoylphorbol-13-acetate and epidermal growth factor-induced transformation of mouse epidermal cell line JB6 (Table 1; [69]). This finding correlates with the inhibition of AP-1 DNA binding and transcriptional activity. The inhibition of AP-1 activity by EGCG was associated with inhibition of JNK activation but not ERK activation. Interestingly, in another study where EGCG blocked the UVB-induced c-Fos activation in a human keratinocyte cell line HaCaT, inhibition of p38 activation was suggested as the major mechanism underlying the effects of EGCG [69].

MAP kinases have been known to involve in variety of key physiologic processes, including cell apoptosis, differentiation, and death. In mammalian cells, three major types of MAP kinases are presented; p38 MAP kinases, ERK, and c-JNK [15]. Activated MAP kinases such as ERK, JNK, and p38 can activate ELK and c-Jun. The second messenger, phosphatidyl inositol-3,4,5-triphosphate synthesized by activate PI3K, which is necessary for phosphorylation of Akt, then Akt directly phosphorylates the proapoptotic protein Bad, thus enhancing the antiapoptotic function of Bcl-xL. In an animal study, it was shown that EGCG (5-20 μmol/L) in concentration dependent manner inhibited the MAP kinase pathway in JB6 mouse epidermal cell line [69]. In NHEK cells, treatment with EGCG inhibited UVB-induced H₂O₂ production concomitant with block of UVB-induced phosphorylation of ERK1/2, JNK, and p38 proteins (Table 1; [70]).

Recently, EGCG has been shown to inhibit MAP kinase pathway and activator protein-1 (AP-1) activity in human colon cancer cells. In a study, orally feeding of EGCG inhibits PI3K pathway in TRAMP model system [71]. The confirm involvement of MAP kinase pathways in the regulation of AP-1 activity by EGCG has been investigated. Treatment of EGCG has been shown to inhibit c-Jun, ERK1/2 phosphorylation and the phosphorylation of ELK1 and MEK1/2 in Ha-ras-transformed human bronchial cells [70]. In contrast to these reports, markedly increase AP-1 factor-associated responses through a MAP kinase signaling mechanism in normal human keratinocytes has been measured by EGCG, suggesting that the signaling mechanism of EGCG action could be markedly different in different cell types [20]. The major pathways that lie downstream of the membrane-associated RTK are also regulated cell cycle and apoptosis. In this cascade, Ras interacts with and activates Raf-1, which in turn phosphorylates and activates MAP/ERK kinase 1/2 (MEK1/2) then phosphorylates ERK1/2. The JNK1/2/3 and p38α/β/γ pathways are parallel MAP kinase cascades in mammalian cells [69]. Because the deregulation of the MAP kinase pathway is frequently seen in a variety of cancers, modulation of MAP kinases by EGCG may provide novel strategies for the prevention or treatment of human cancer.

5.4.4. Inhibition of epidermal growth factor receptor (EGFR)–mediated signal transduction pathway

The EGFR (ErbB-1; HER1 in humans) is a cell surface glycoprotein receptor with an extracellular ligand-binding domain, a single transmembrane region, and an intracellular domain that exhibits intrinsic tyrosine kinase activity. The EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). Mutations that lead to EGFR overexpression (known as upregulation) or overexpression have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme. A blockade of EGFR may lead the cancer cells to enter apoptosis [12]. Therefore, inhibition of EGFR abrogates the invasive potential of the cancer cells. Overexpression of HER-2/neu, an oncogene in the EGFR tyrosine kinase superfamily, is observed in breast, prostate, ovarian and lung cancers and it is recognized as a target for cancer therapy [12]. Downstream events, the phosphorylation of ERK, STAT3, and Akt were subsequently blocked by the treatment with EGCG (Table 1; [71]). However, the cells were pre-incubated with EGCG before the addition of TGF-α, resulting the inhibition of EGFR-dependent STAT3 activation subsequently retarded VEGF synthesis in the cancer cells. The inhibitory effect of NFκB by EGCG also contributed to the overall VEGF down-regulation. Treatment with EGCG inhibited the constitutive ligand-mediated activation of the EGFR in both YCU-H891 head and neck squamous cell carcinoma and MDA-MB-231 breast carcinoma cell lines, indicating that it has the potential to break the autocrine loops that are established in several advanced cancers [72]. The results suggested that blocking the EGFR signaling by EGCG would potentially inhibit both cancer cell proliferation and angiogenesis.

Recently, Ahmad observed that EGCG suppresses the expression of IL-6 and IL-8 in vitro [73]. EGCG has been shown to suppress the production of VEGF in swine granulosa cells and breast carcinoma cells [73]. EGCG inhibits EGFR signaling pathway, most likely through the direct inhibition of ERK1/2 and Akt kinases [58]. EGCG blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells [6]. EGCG binds to a specific metastasis associated 67 kDa laminin receptor that is expressed on a variety of tumor cells [74]. Cells were treated with all trans-retinoic acid that the anticancer action of EGCG is mediated by laminin receptor and it allows EGCG to bind to the cell surface using a subtraction cloning strategy involving cDNA libraries. The cell-laminin interaction via receptor 67LR is a key step in several signaling pathways and kinase-phosphatase cascades. Authors found an association between 67LR and the integrin α6 subunit, which is a part of laminin-binding integrins α₆β₄ and α₆β₁. When EGCG incorporated in plasma membrane directly interacts with Platelet-derived Growth Factor-BB (PDGF-BB), thereby preventing specific receptor binding leading to the inhibitory effects of EGCG on PDGF-induced cell signaling and mitogenesis. Moreover, Givant-Horwitz and associates [75] reported that in human colon cancer cells, EGCG inhibits growth and activation of EGFR and human EGFR-2 signaling pathways. Based on these data, it was suggested that may be existence of EGCG receptor. This suggestion awaits follow-up and confirmation.

5.4.5. Inhibition of overexpression of cyclooxygenase-2 (COX-2)

COX is prostaglandin H synthase, the key regulatory enzyme for prostaglandin synthesis is transcribed from two distinct genes (COX-1 & COX-2). COX-1 is constitutively expressed in many tissues, but the expression of COX-2 is regulated by a variety of factors, such as mitogens, tumor promoters, cytokines, and growth factors. Inappropriate COX-2 activity has been observed in practically every premalignant and malignant condition involving the colon, liver, pancreas, breast, lung, bladder, skin, stomach, head and neck, and esophagus [15]. Several transcription factors including AP-1, and NFκB can stimulate COX-2 transcription [15]. EGCG inhibits mitogen-stimulated COX-2 expression in androgen-sensitive LNCaP and androgen-insensitive PC-3 human prostate carcinoma cells [76]. It has been shown that EGCG reduces the activity of COX-2 following interleukin-1A stimulation of human chondrocytes [77]. EGCG exhibited COX inhibition in LPs-induced macrophages (Table 1). Pretreatment with green tea extract enriched with EGCG inhibited COX-2 expression induced by TPA in mouse skin. EGCG can down-regulate COX-2 in TPA-stimulated human mammary cells (MCF-10A) in culture [78]. Recent clinical research findings strongly suggest that development of chemopreventive compounds, which can inhibit COX-2 expression preferably without affecting COX-1, is a high priority for cancer research.

5.4.6. Inhibition of proteasome activity

The proteasome is a massive multicatalytic protease complex that is responsible for degrading most of the damage or misfold proteins. The proteasomal degradation pathway is essential for many cellular processes, including cell proliferation, down-regulation of cell death, development of drug resistance in human tumor cells, regulation of gene expression and responses to oxidative stress, suggesting the use of proteasome inhibitors as potential novel anticancer drugs. In vitro and in vivo studies shown that EGCG inhibits the chymotrypsin-like but not trypsin-like activity of the proteasome. Inhibition of the chymotrypsin-like activity of the proteasome has been associated with induction of tumor cell apoptosis. The catalytic activities of the 20S/26S proteasome complex were inhibited by EGCG, resulting in intracellular accumulation of IkBα and subsequent inhibition of NFκB activation (Table 1; [79]). This finding suggests that the proteasome is a cancer related molecular target of EGCG and that inhibition of the proteasome activity by this phytomolecule may contribute to its cancer preventive potential. Application of EGCG resulted in G0/G1 cell cycle arrest and accumulation of p27 and IkBα in LNCaP prostate cancer cells with both of which are targets for proteasomes [80]. The difference of effective concentrations in cell-free systems (IC₅₀ 0.09–0.2 mM) and in cell lines (IC₅₀ 1–10 mM) suggests that EGCG may bind nonspecifically to proteins or other macromolecules in the cells, and therefore lower the effective concentration of EGCG at the active site of the protease and stability and cellular uptake of EGCG may also be an important factor.

5.5. Inhibition of epigenetic modifications

Epigenetics refers to heritable changes that are not encoded in the DNA sequence itself, but play an important role in the control of gene expression. In mammals, epigenetic mechanisms include changes in DNA methylation, histone modifications and non-coding RNAs. The tail and globular domains of eukaryotic nucleosomal histones can by modified by these epigenetic events and alter the gene expression [81]. Among them, DNA methylation of cytosines at CpG dinucleotides is perhaps the most extensively studied epigenetic modification in mammals with profound functional implications for wide range of cellular processes [81]. Although epigenetic changes are heritable in somatic cells, these modifications are also potentially reversible, which makes them attractive and promising avenues for tailoring cancer preventive and therapeutic strategies.

DNA methylation is a covalent biochemical modification, resulting in the addition of a methyl group to the 5^th carbon position in the pyramidine ring of cytosine located in the CpG dinucleotides. Hypermethylation often limits the accessibility of transcription factors to promoters, promote the methyl-CpG binding domain (MBD) binding, which results in recruitment of additional silencing-associated proteins, and ultimately, gene silencing[81]. An estimated 60% of mammalian gene promoters contain CpG islands, many of these genes belongs to the house keeping category that are usually unmethylated and transcriptionally activate [81]. It has been well known that CpG islands in certain genes, especially tumor suppressor genes, often become aberrantly hypermethylated during the development of cancer (Fig. 4a & b). Patterns of DNA methylation are established by the coordinated action of DNMTs and associated factors, such as the polycomb proteins, in the presence of S-adenosylmethionine (SAM) that serves as a methyl donor for methyl group. The mammalian DNMT family include for active members, DNMT1, DNMT3A, DNMT3B, and DNMT3L. Demethylation of SAM results in the formation of S-adenosylhomocysteine (SAH), and evidences from clinical studies demonstrated that SAH is a potent inhibitor of DNMT [25].

EGCG can form hydrogen bonds with different residues in the catalytic pocket of DNMT, thus acting as a direct inhibitor of DNMT1 (Table1; Fig. 4c). The inhibition of DNMT may prevent the methylation of the newly synthesized DNA strand, resulting in the reversal of the hypermethylation and the re-expression of the silenced genes [25]. Finally, it has been shown that EGCG is also an efficient blocker of DHFR. EGCG acts through interaction with folic acid metabolism in cells, causing the inhibition of nucleic acid (DNA & RNA) synthesis and altering pattern of DNA methylation. EGCG was shown to affect various biologic pathways and inhibits DNMTs activity in human cancer cell lines (Fig. 4c). EGCG binds to DNMT1 and blocks the enzyme’s active site. EGCG generates oxidizing agent H₂O₂ in a substantial amount, which is oxidized to DNMTs and other proteins might contribute to its inhibition of DNA methylation as well [25, 82]. The same action, however, may also cause oxidative damage and substantially increase its cytotoxicity. EGCG caused a concentration and time-dependent reversal of hypermethylation of TSGs such as p16, RAR, MGMT, and MLH1 genes in human esophageal cancer cells [26, 83]. Treatment of human colon cancers and prostate cancer cells with EGCG reactivated some methylation-silenced genes. Since then, several groups found similar in vitro results. Partial demethylation of hypermethylated RARb by EGCG was demonstrated in breast cancer cells such as MCF-7 and MDA-MB-231 [38]. EGCG partially reversed the hypermethylation status of the RECK gene and significantly enhanced the expression level of RECK mRNA in oral cancer cells. Repetitive elements such as p16, RARb, MAGE-A1, MAGE-B2 and Alu in T24, HT29, and PC3 cell lines for their DNA methylation levels and their mRNA expression levels using several demethylating agents [84]. Recently, in vivo study showed that topical treatment of EGCG in hydrophilic cream inhibits UVB induced global DNA hypomethylation pattern in chronically UVB-exposed mice. Treatment of MCF-7 breast cancer cells with EGCG resulted in activation of several genes and decrease in hTERT promoter methylation [38].

5.6. Inhibition of dihydrofolate reductase (DHFR) and telomerase

DHFR, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. DHFR as a novel modulator of β-catenin and GSK3 signaling and raise several implications for clinical and can use for inflammatory disease and cancer. Recently, it was reported that EGCG acts as a potential inhibitor of DHFR [85]. It exhibited kinetic characteristics of a slow tight binding inhibitor of 7,8-dihydrofolate reduction with bovine liver DHFR (Ki 0.11 mM). The very low Ki value observed for bovine liver DHFR might be due to the fact that very low levels of the enzyme were used in the assay, and the inhibition was due to the strong binding activity of EGCG to the enzyme (a slow tight binding inhibitor, as reported), not necessarily by binding to the active site (Table1; [86]). But EGCG acted as a classic reversible competitive inhibitor with chicken liver DHFR with a much larger Ki (10.3 mM). Folate depletion increased the sensitivity of these cell lines to the antifolate activities of EGCG. Telomerase is important for maintaining the telomere nuclear protein endcaps of the chromosome and it has been shown to be overexpressed in many human cancers. Long-term treatment with EGCG (5–10 mM) was reported to inhibit telomerase and induce cell senescence [87]. At high nanomolar to low micromolar concentrations of EGCG inhibited telomerase activity in cell-free systems at neutral pH. The authors were concluded that EGCG decomposes by auto-oxidation to form a galloyl radical, which can covalently modify telomerase activity [88]. In an animal study, treatment of mice bearing telomerase-positive colon cancer xenografts (HCT-L2) with 1.2 mg of EGCG per day for 80 d resulted in a 50% inhibition in tumor size [87]. Whereas mice bearing telomerase-negative tumors of the same parent cell line (HCT-S2R) were unresponsive to EGCG treatment. This interesting line of observation should be extended into other cell lines.

5.7. Inhibition of angiogenesis

Angiogenesis is a complex event which requires endothelial cell sprouting, lumen formation, tubulogenesis and is regulated by the coordinated action of different transcription factors [6]. Their interaction leads to endothelial cell differentiation and acquisition of arterial, venous and lymphatic properties. The transcription factors regulate the correct organization of the vascular system, controlling excessive endothelial growth and inducing apoptosis. FOXO transcription factors play a crucial role in the regulation of tissue homeostasis in organs such as the pancreas and the ovaries and complex diseases such as diabetes and cancer. We have recently shown that EGCG inhibits angiogenesis by enhancing FOXO transcriptional activity [28]. Inhibition of AKT and MEK kinases synergistically induced FOXO transcriptional activity, which was further enhanced in the presence of EGCG. Phosphorylation deficient mutants of FOXO induced FOXO transcriptional activity, inhibited HUVEC cell migration and capillary tube formation. Inhibition of FOXO phosphorylation also enhanced antiangiogenic effects of EGCG through transcriptional activation of FOXO [28]. Authors concluded that the activation of FOXO transcription factors through inhibition of these two pathways may have physiological significance in management of diabetic retinopathy, rheumatoid arthritis, psoriasis, cardiovascular diseases and cancer. Recently, Bartholome et al. [89] reported that EGCG at 1 μM stimulated FOXO transcription factor nuclear accumulation and DNA binding activity. EGCG decreases ET-1 expression and secretion from endothelial cells, in part, via Akt- and AMPK-stimulated FOXO1 regulation of the ET-1 promoter. These findings may be relevant to beneficial cardiovascular actions of green tea [90]. Moreover, EGCG exerts its insulin mimetic effects at least in part by phosphorylation of the FOXOs through a mechanism that is similar but not identical to insulin and IGF-1 induced FOXO phosphorylation [91].

5.8. Possible modulation of miRNA expression

Small molecules known as MicroRNAs are a contemporary class of noncoding endogenous RNA molecules, generating great excitement in the clinical and scientific communities. miRNAs have been recently discovered as key regulators of gene expression by controlling the translation of a specific type of RNA called messenger RNA which relays the genetic instructions for making proteins [92]. Previous research has indicated that miRNAs are express in a tissue-specific manner and control a wide spectrum of biological processes including cell proliferation, apoptosis and differentiation. Although miRNA are vital to normal cell physiology, aberrant expression of these small non-coding RNAs has been linked to carcinogenesis [92]. The recent discovery that miRNA expression is frequently dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, which warrants extensive investigation to further elucidate their precise role in malignancy. Although there is still limited evidence, recent reports have identified that dietary agents can also alter gene expression by targeting various oncogenic or tumor suppressive miRNAs. One of the interesting features of miRNAs is that similar to regular genes, their own expression can be regulated by other DNA methylation. The influence of miRNA on the epigenetic machinery and the reciprocal epigenetic regulation of miRNA expression suggest that its aberrant expression during carcinogenesis has an important implication for global regulation of cancer. Additionally, interaction among various components of the epigenetic machinery re-emphasizes the integrated nature of epigenetic mechanisms involved in the maintenance of global gene expression patterns in mammals. Treatment of human hepatocellular carcinoma HepG2 cells with EGCG has been recently found to inhibit the expression of oncogenic miRNA and induce level of tumor suppressive miRNAs (Fig. 5). Treatment of HepG2 with EGCG resulted in the expressions of 61 miRNAs. miR-16, one of the miRNAs up-regulated by EGCG, is known to regulate the anti-apoptotic protein Bcl-2, and interestingly EGCG treatment induced apoptosis and downregulated Bcl-2 in HepG2 cells [93]. Transfection with anti-miR-16 inhibitor suppressed miR-16 expression and counteracted the EGCG effects on Bcl-2 down-regulation and also induction of apoptosis in cells.

5.9. Miscellaneous mechanisms

The uPA is a trypsin-like protease that converts the zymogen plasminogen into active plasmin. It is highly expressed in human cancer and has the ability to prevent apoptosis, stimulate angiogenesis, mitogenesis, cell migration, and to modulate cell adhesion [94]. uPA, one of the hydrolases implicated in the degradation of the extracellular matrix and tumor invasion, is directly inhibited by EGCG [33]. Inhibition of uPA can decrease tumor size or even cause complete remission of cancers in mice. EGCG-induced suppression of uPA promoter activity as well as expression appears to be mediated by blocking ERK and p38 MAP kinase, but not JNK and AKT. Jankun et al. [33] showed that EGCG binds to urokinase, blocking His⁵⁷ and Ser¹⁹⁵ of the uPA catalytic triad, and extending toward Arg³⁵ from a positively charged loop of uPA. Thus, it was suggested that the cancer prevention action of EGCG is mediated by inhibition of uPA. EGCG was found to be a potent inhibitor of uPA expression in human fibrosarcoma HT 1080 cells. In addition, EGCG inhibited uPA promoter activity and also destabilized uPA mRNA [95]. EGCG was also shown to affect MMPs directly and indirectly. EGCG also inhibited the activation of MMPs by MT1-MMP [96]. EGCG increased the expression of the tissue inhibitor of MMPs (TIMP1 and 2) at even lower concentrations (~1 μM), which provides an additional mechanism to suppress the activity of MMPs. The activities of secreted MMP2 and MMP9 were inhibited by EGCG with IC₅₀ values of 8–13 μM [96]. These activities may contribute to the reported inhibition of metastasis and invasion following treatment of tumor-bearing mice with EGCG. Most recently, in several human colon carcinoma cell lines, EGCG was found to inhibit the activity of topoisomerase I at 3–17 μM concentration. By comparison, EGCG at concentrations up to 550 μM did not inhibit topoisomerase II activity [97]. This is an interesting mechanism of action for EGCG given the relatively low concentrations necessary for inhibition and the correlation of topoisomerase I inhibition with phenomena, such as DNA damage, cell cycle arrest, and induction of apoptosis [97].

6. Clinical trails

Limited data are currently available from EGCG chemoprevention trials. EGCG offers several potential clinical advantages compared to other traditional cancer drugs. In contrast, EGCG is globally available as tea, is inexpensive to isolate, and can be administered orally [98]. While, traditional cancer drugs are often destroy some healthy cells along with cancerous cells [99]. EGCG appears to target biochemical and genetic functions unique to cancer cells [53]. Some of the anticarcinogenic agents currently in use have toxic adverse effects, but data from clinical trials reported to date suggest that EGCG has a very acceptable safety profile [53]. These benefits support further development of EGCG as a potentially useful anticarcinogenic agent. A prospective cohort study with over 8,000 individuals revealed that the daily consumption of green tea resulted in delayed cancer onset and a follow-up study of breast cancer patients found that stages I and II breast cancer patients experienced a lower recurrence rate and longer disease free period [100]. Moreover, EGCG delivered in the form of capsule (200 mg p.o.) for 12 weeks has been reported to be effective in the patients with human papilloma virus–infected cervical lesions [37]. The positive results observed in phase II and phase III clinical trials along with exciting preclinical results indicate that ways and means to take EGCG “from bench to real-life situations” are on the horizon.

Go to:

7. Summery, conclusion and future prospects

Naturally occurring antioxidant substances such as polyphenols and flavonoids that are derived from herbs, fruits, vegetable and medicinal plants provides a new insight in prevention and therapy of cancer. The mechanisms of action of several dietary chemopreventive agents have gained considerable attention in cancer research. There is extensive research going on in elucidating the molecular mechanisms of cancer chemoprevention by green tea catchine EGCG. Although there are several studies supporting the preventive potential of EGCG against cancer, a proper understanding of the mechanisms by which EGCG reduces the risk is necessary to establish its efficacy for the population where it could be most useful. Despite the demonstration of cancer prevention by green tea and their polyphenolic compounds in many animal studies, epidemiological studies have yielded mixed results concerning the effectiveness of EGCG as a superb medicine for prevention and therapy of cancer in humans. Several mechanisms to explain the chemopreventive potentials of EGCG have been presented, among which its effect to target specific cell signaling pathways have received considerable attention for regulating cellular proliferation and apoptosis. The diversified effects of EGCG may explain its broad pharmacologic activities in modulating cellular signaling pathways in cells. EGCG, in addition to other mechanisms, at human achievable dose, is known to activate cell death signals and induce apoptosis in precancerous or cancer cells, resulting in the inhibition of tumor development and/or progression. Importantly, these anti-proliferative and proapoptotic effects of EGCG have been shown to be selective for cancer cells, as normal cells were not affected by its treatment. In cancer cells, EGCG also causes inhibition of the activity of specific receptor tyrosine kinases and related downstream pathways of signal transduction. This review summarizes recent research data focusing on EGCG induced cellular signal transduction events that seems to have implications in the inhibition of cell proliferation and transformation, induction of apoptosis of preneoplastic and neoplastic cells as well as inhibition of angiogenesis, tumor invasion, and metastasis.

Most modern medicines currently available for treating cancers are very expensive, toxic, and less effective in treating the disease. Thus, one must investigate further in detail the EGCG derived from green tea, described traditionally, for the prevention and treatment of cancer and other diseases. The understanding of the cell signaling pathways and the molecular events leading to carcinogenesis will provide more insight into the identification and development of potent chemopreventive/chemotherapeutic agents that specifically target these pathways. Future studies from in vitro systems should be integrated with studies in vivo, especially in ongoing clinical trials, to evaluate the applicability of these mechanisms in cancer prevention in humans. To fully elucidate the molecular mechanisms of action of EGCG with existing therapy in future studies, more in-depth in vitro and in vivo experiments are needed.

жүктеу/скачать 1.88 Mb.

Достарыңызбен бөлісу: